Vaquero E, Lazzarin N, Valensise H, Menghini S, Di Pierro G, Cesa F, Romanini C
Department of Obstetrics and Gynecology, University of Rome Tor Vergata, Fatebenefratelli Hospital, Isola Tiberina, Italy.
Am J Reprod Immunol. 2001 Mar;45(3):174-9. doi: 10.1111/j.8755-8920.2001.450309.x.
To compare the use of intravenous immunoglobulins (IVIG) with prednisone plus low-dose aspirin (LDA) in treating pregnant women with a history of recurrent fetal loss having the antiphospholipid antibody (aPL), in terms of live-birth rate and maternal and perinatal morbidity.
A prospective, two-centers trial study included 82 recurrent aborters with aPL syndrome. Twenty-nine were treated with prednisone and LDA in one center, 53 received IVIG in the other center. Maternal and fetal outcomes and pregnancy complications were compared between groups.
Live-birth rates were equivalent between groups (78 vs 76%). Mean birth weight was higher in the IVIG group than in the prednisone plus LDA group. In the prednisone- plus LDA-treated patients, gestational hypertension and gestational diabetes were found significantly more often than in the IVIG-treated group (14 vs 5% and 14 vs 5%, respectively).
In patients with aPL syndrome, IVIG treatment improved pregnancy outcome, with significantly lower pregnancy complication rates, when compared with prednisone plus LDA therapy.
比较静脉注射免疫球蛋白(IVIG)与泼尼松联合小剂量阿司匹林(LDA)在治疗有复发性流产史且患有抗磷脂抗体(aPL)的孕妇时,在活产率以及孕产妇和围产期发病率方面的差异。
一项前瞻性、双中心试验研究纳入了82例患有aPL综合征的复发性流产患者。其中29例在一个中心接受泼尼松和LDA治疗,53例在另一个中心接受IVIG治疗。对两组之间的母婴结局和妊娠并发症进行比较。
两组的活产率相当(分别为78%和76%)。IVIG组的平均出生体重高于泼尼松联合LDA组。在接受泼尼松联合LDA治疗的患者中,妊娠期高血压和妊娠期糖尿病的发生率显著高于IVIG治疗组(分别为14%对5%和14%对5%)。
在患有aPL综合征的患者中,与泼尼松联合LDA治疗相比,IVIG治疗改善了妊娠结局,妊娠并发症发生率显著降低。